FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285010157> ?p ?o ?g. }

• W4285010157 endingPage "1439" @default.
• W4285010157 startingPage "1439" @default.
• W4285010157 abstract "Chronic hepatitis B is a critical cause of many serious liver diseases such as hepatocellular carcinoma (HCC). The main challenges in hepatitis B treatment include the rebound of hepatitis B virus (HBV)-related antigen levels after drug withdrawal and the immunosuppression caused by the virus. Herein, we demonstrate that the HBV-related antigen can be effectively inhibited and antiviral immunity can be successfully reactivated through codelivery of the small interfering RNA (siRNA) targeting HBV X protein (HBx) and the plasmid encoding interleukin 12 (pIL-12) to hepatocytes and immune cells. After being treated by the siRNA/pIL-12 codelivery system, HBx mRNA and hepatitis B surface antigen (HBsAg) are dramatically reduced in HepG2.215 cells. More importantly, the downregulated CD47 and programmed death ligand 1 (PD-L1) and the upregulated interferon-β promoter stimulator-1 (IPS-1), retinoic acid-inducible gene-1 (RIG-1), CD80, and human leukocyte antigen-1 (HLA-1) in treated HepG2.215 cells indicate that the immunosuppression is reversed by the codelivery system. Furthermore, the codelivery system results in inhibition of extracellular regulated protein kinases (ERK) and phosphoinositide-3-kinase (PI3K)/protein kinase B (Akt) pathways, as well as downregulation of B-cell lymphoma-2 (Bcl-2) and upregulation of p53, implying its potential in preventing the progression of HBV-induced HCC. In addition, J774A.1 macrophages treated by the codelivery system were successfully differentiated into the M1 phenotype and expressed enhanced cytokines with anti-hepatitis B effects such as interleukin 6 (IL-6) and tumor necrosis factor-α (TNF-α). Therefore, we believe that codelivery of siRNA and pIL-12 can effectively inhibit hepatitis B virus, reverse virus-induced immunosuppression, reactivate antiviral immunity, and hinder the progression of HBV-induced hepatocellular carcinoma. This investigation provides a promising approach for the synergistic treatment of HBV infection." @default.
• W4285010157 created "2022-07-12" @default.
• W4285010157 creator A5017398058 @default.
• W4285010157 creator A5020288245 @default.
• W4285010157 creator A5021775481 @default.
• W4285010157 creator A5038811887 @default.
• W4285010157 creator A5043166309 @default.
• W4285010157 creator A5046248892 @default.
• W4285010157 creator A5077143573 @default.
• W4285010157 date "2022-07-09" @default.
• W4285010157 modified "2023-10-16" @default.
• W4285010157 title "Codelivery of HBx-siRNA and Plasmid Encoding IL-12 for Inhibition of Hepatitis B Virus and Reactivation of Antiviral Immunity" @default.
• W4285010157 cites W1933670444 @default.
• W4285010157 cites W1984550821 @default.
• W4285010157 cites W2005166644 @default.
• W4285010157 cites W2009219530 @default.
• W4285010157 cites W2051575673 @default.
• W4285010157 cites W2071180621 @default.
• W4285010157 cites W2075065864 @default.
• W4285010157 cites W2077258861 @default.
• W4285010157 cites W2080538774 @default.
• W4285010157 cites W2098604972 @default.
• W4285010157 cites W2111205315 @default.
• W4285010157 cites W2137303998 @default.
• W4285010157 cites W2173698250 @default.
• W4285010157 cites W2341442578 @default.
• W4285010157 cites W2528574508 @default.
• W4285010157 cites W2575806121 @default.
• W4285010157 cites W2604987759 @default.
• W4285010157 cites W2611875906 @default.
• W4285010157 cites W2774064974 @default.
• W4285010157 cites W2791839818 @default.
• W4285010157 cites W2793011605 @default.
• W4285010157 cites W2803367030 @default.
• W4285010157 cites W2886112419 @default.
• W4285010157 cites W2900235043 @default.
• W4285010157 cites W2900561127 @default.
• W4285010157 cites W2954121849 @default.
• W4285010157 cites W2963405480 @default.
• W4285010157 cites W2965094856 @default.
• W4285010157 cites W2967454885 @default.
• W4285010157 cites W2970872004 @default.
• W4285010157 cites W2979296404 @default.
• W4285010157 cites W2991095295 @default.
• W4285010157 cites W3001577527 @default.
• W4285010157 cites W3006723865 @default.
• W4285010157 cites W3017499363 @default.
• W4285010157 cites W3018993583 @default.
• W4285010157 cites W3019513613 @default.
• W4285010157 cites W3040241190 @default.
• W4285010157 cites W3040851638 @default.
• W4285010157 cites W3045935025 @default.
• W4285010157 cites W3047035599 @default.
• W4285010157 cites W3081809528 @default.
• W4285010157 cites W3084269058 @default.
• W4285010157 cites W3089298983 @default.
• W4285010157 cites W3091951350 @default.
• W4285010157 cites W3092515320 @default.
• W4285010157 cites W3097318247 @default.
• W4285010157 cites W3097969124 @default.
• W4285010157 cites W3106908673 @default.
• W4285010157 cites W3110901574 @default.
• W4285010157 cites W3120003695 @default.
• W4285010157 cites W3120808808 @default.
• W4285010157 cites W3130256703 @default.
• W4285010157 cites W3160938771 @default.
• W4285010157 cites W3168097989 @default.
• W4285010157 cites W3182758513 @default.
• W4285010157 cites W3184345612 @default.
• W4285010157 cites W3198295868 @default.
• W4285010157 cites W3200727625 @default.
• W4285010157 cites W3212636034 @default.
• W4285010157 cites W4213082500 @default.
• W4285010157 doi "https://doi.org/10.3390/pharmaceutics14071439" @default.
• W4285010157 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35890334" @default.
• W4285010157 hasPublicationYear "2022" @default.
• W4285010157 type Work @default.
• W4285010157 citedByCount "3" @default.
• W4285010157 countsByYear W42850101572023 @default.
• W4285010157 crossrefType "journal-article" @default.
• W4285010157 hasAuthorship W4285010157A5017398058 @default.
• W4285010157 hasAuthorship W4285010157A5020288245 @default.
• W4285010157 hasAuthorship W4285010157A5021775481 @default.
• W4285010157 hasAuthorship W4285010157A5038811887 @default.
• W4285010157 hasAuthorship W4285010157A5043166309 @default.
• W4285010157 hasAuthorship W4285010157A5046248892 @default.
• W4285010157 hasAuthorship W4285010157A5077143573 @default.
• W4285010157 hasBestOaLocation W42850101571 @default.
• W4285010157 hasConcept C159047783 @default.
• W4285010157 hasConcept C203014093 @default.
• W4285010157 hasConcept C2522874641 @default.
• W4285010157 hasConcept C2780593183 @default.
• W4285010157 hasConcept C502942594 @default.
• W4285010157 hasConcept C67567795 @default.
• W4285010157 hasConcept C86803240 @default.
• W4285010157 hasConceptScore W4285010157C159047783 @default.
• W4285010157 hasConceptScore W4285010157C203014093 @default.
• W4285010157 hasConceptScore W4285010157C2522874641 @default.

• next